Modality
Vaccine
MOA
JAK1i
Target
MET
Pathway
Apoptosis
Wilms
Development Pipeline
Preclinical
~Sep 2021
→ ~Dec 2022
Phase 1
~Mar 2023
→ ~Jun 2024
Phase 2
Sep 2024
→ Sep 2029
Phase 2Current
NCT03461289
2,383 pts·Wilms
2024-09→2029-09·Recruiting
2,383 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-10-265mo agoFast Track· Wilms
2029-09-143.5y awayPh3 Readout· Wilms
Trial Timeline
Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
P2/3
Recruit…
Catalysts
Fast Track
2025-10-26 · 5mo ago
Wilms
Ph3 Readout
2029-09-14 · 3.5y away
Wilms
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03461289 | Phase 2/3 | Wilms | Recruiting | 2383 | EASI-75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-7458 | Johnson & Johnson | Phase 1/2 | PD-1 | |
| Geliderotide | Sanofi | Phase 1/2 | PRMT5 | |
| SNY-5783 | Sanofi | Phase 1/2 | MET | |
| Pexaosocimab | Daiichi Sankyo | Phase 2 | PD-1 | |
| Sotosacituzumab | Vertex Pharma | Phase 1 | MET | |
| Adagratapinarof | Vertex Pharma | Preclinical | BCMA | |
| ARG-1924 | Argenx | Preclinical | DLL3 | |
| ROI-1081 | Roivant Sciences | Phase 1/2 | PI3Kα | |
| RVM-274 | Revolution Medicines | Phase 3 | MET | |
| Talazasiran | Kymera | NDA/BLA | MET |